Literature DB >> 19159226

Fluorescence lifetime of actin in the familial hypertrophic cardiomyopathy transgenic heart.

P Mettikolla1, R Luchowski, I Gryczynski, Z Gryczynski, D Szczesna-Cordary, J Borejdo.   

Abstract

Clinical studies have revealed that the D166V mutation in the ventricular myosin regulatory light chain (RLC) can cause a malignant phenotype of familial hypertrophic cardiomyopathy (FHC). It has been proposed that RLC induced FHC in the heart originates at the level of the myosin cross-bridge due to alterations in the rates of cross-bridge cycling. In this report, we examine whether the environment of an active cross-bridge in cardiac myofibrils from transgenic (Tg) mice is altered by the D166V mutation in RLC. The cross-bridge environment was monitored by tracking the fluorescence lifetime (tau) of Alexa488-phalloidin-labeled actin. The fluorescence lifetime is the average rate of decay of a fluorescent species from the excited state, which strongly depends on various environmental factors. We observed that the lifetime was high when cross-bridges were bound to actin and low when they were dissociated from it. The lifetime was measured every 50 ms from the center half of the I-band during 60 s of rigor, relaxation and contraction of muscle. We found no differences between lifetimes of Tg-WT and Tg-D166V muscle during rigor, relaxation and contraction. The duty ratio expressed as a fraction of time that cross-bridges spend attached to the thin filaments during isometric contraction was similar in Tg-WT and Tg-D166V muscles. Since independent measurements showed a large decrease in the cross-bridge turnover rate in Tg-D166V muscle compared to Tg-WT, the fact that the duty cycle remains constant suggests that the D166V mutation of RLC causes a decrease in the rate of cross-bridge attachment to actin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19159226      PMCID: PMC2701482          DOI: 10.1021/bi801629d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  30 in total

Review 1.  The young competitive athlete with cardiovascular abnormalities: causes of sudden death, detection by preparticipation screening, and standards for disqualification.

Authors:  Barry J Maron
Journal:  Card Electrophysiol Rev       Date:  2002-02

Review 2.  Why choose myofibrils to study muscle myosin ATPase?

Authors:  Corinne Lionne; Bogdan Iorga; Robin Candau; Franck Travers
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

3.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

4.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Authors:  B J Maron; I Olivotto; P Spirito; S A Casey; P Bellone; T E Gohman; K J Graham; D A Burton; F Cecchi
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

Review 5.  Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy.

Authors:  Daniel J Lips; Leon J deWindt; Dave J W van Kraaij; Pieter A Doevendans
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

6.  Familial hypertrophic cardiomyopathy-linked alterations in Ca2+ binding of human cardiac myosin regulatory light chain affect cardiac muscle contraction.

Authors:  Danuta Szczesna-Cordary; Georgianna Guzman; Shuk-Shin Ng; Jiaju Zhao
Journal:  J Biol Chem       Date:  2003-11-01       Impact factor: 5.157

7.  Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice.

Authors:  W Glenn L Kerrick; Katarzyna Kazmierczak; Yuanyuan Xu; Yingcai Wang; Danuta Szczesna-Cordary
Journal:  FASEB J       Date:  2008-11-05       Impact factor: 5.191

Review 8.  Regulatory light chains of striated muscle myosin. Structure, function and malfunction.

Authors:  Danuta Szczesna
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2003-06

9.  Changes in orientation of actin during contraction of muscle.

Authors:  J Borejdo; A Shepard; D Dumka; I Akopova; J Talent; A Malka; T P Burghardt
Journal:  Biophys J       Date:  2004-04       Impact factor: 4.033

10.  Studies on conformation of F-actin in muscle fibers in the relaxed state, rigor, and during contraction using fluorescent phalloidin.

Authors:  E Prochniewicz-Nakayama; T Yanagida; F Oosawa
Journal:  J Cell Biol       Date:  1983-12       Impact factor: 10.539

View more
  9 in total

1.  Familial hypertrophic cardiomyopathy can be characterized by a specific pattern of orientation fluctuations of actin molecules .

Authors:  J Borejdo; D Szczesna-Cordary; P Muthu; N Calander
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

2.  Toward the measurement of multiple fluorescence lifetimes in flow cytometry: maximizing multi-harmonic content from cells and microspheres.

Authors:  Patrick Jenkins; Mark A Naivar; Jessica P Houston
Journal:  J Biophotonics       Date:  2015-02-26       Impact factor: 3.207

3.  Phosphorylation of myosin regulatory light chain has minimal effect on kinetics and distribution of orientations of cross bridges of rabbit skeletal muscle.

Authors:  Divya Duggal; Janhavi Nagwekar; Ryan Rich; Krishna Midde; Rafal Fudala; Ignacy Gryczynski; Julian Borejdo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-11-27       Impact factor: 3.619

4.  Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions.

Authors:  D Duggal; J Nagwekar; R Rich; W Huang; K Midde; R Fudala; H Das; I Gryczynski; D Szczesna-Cordary; J Borejdo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

5.  Cross-bridge kinetics in myofibrils containing familial hypertrophic cardiomyopathy R58Q mutation in the regulatory light chain of myosin.

Authors:  P Mettikolla; N Calander; R Luchowski; I Gryczynski; Z Gryczynski; J Zhao; D Szczesna-Cordary; J Borejdo
Journal:  J Theor Biol       Date:  2011-06-24       Impact factor: 2.691

6.  Kinetics of a single cross-bridge in familial hypertrophic cardiomyopathy heart muscle measured by reverse Kretschmann fluorescence.

Authors:  Prasad Mettikolla; Nils Calander; Rafal Luchowski; Ignacy Gryczynski; Zygmunt Gryczynski; Julian Borejdo
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

7.  Observing cycling of a few cross-bridges during isometric contraction of skeletal muscle.

Authors:  P Mettikolla; N Calander; R Luchowski; I Gryczynski; Z Gryczynski; J Borejdo
Journal:  Cytoskeleton (Hoboken)       Date:  2010-06

8.  Single molecule kinetics in the familial hypertrophic cardiomyopathy D166V mutant mouse heart.

Authors:  Priya Muthu; Prasad Mettikolla; Nils Calander; Rafal Luchowski; Ignacy Gryczynski; Zygmunt Gryczynski; Danuta Szczesna-Cordary; J Borejdo
Journal:  J Mol Cell Cardiol       Date:  2009-11-13       Impact factor: 5.000

9.  A Novel Method of Determining the Functional Effects of a Minor Genetic Modification of a Protein.

Authors:  Janhavi Nagwekar; Divya Duggal; Krishna Midde; Ryan Rich; Jingsheng Liang; Katarzyna Kazmierczak; Wenrui Huang; Rafal Fudala; Ignacy Gryczynski; Zygmunt Gryczynski; Danuta Szczesna-Cordary; Julian Borejdo
Journal:  Front Cardiovasc Med       Date:  2015-11-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.